Evaluating Avive+ Soft Tissue Matrix for Prevention of Superficial Radial Nerve Morbidity Following Radial Forearm Free Flap Harvest

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alabama at Birmingham

About this trial

Radial forearm free flap (RFFF) reconstruction is commonly used for head and neck defects but is associated with donor-site morbidity, including neuropathic pain and sensory disturbance. This randomized controlled pilot study evaluates whether placement of a soft tissue matrix over the superficial radial nerve at the donor site reduces neuropathic pain and improves sensory outcomes compared to standard closure alone.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Undergoing RFFF for head and neck reconstruction

Treated at University of Alabama at Birmingham

Able to provide informed consent

Disqualifiers

Reconstruction using a non-RFFF free flap

Pre-existing ipsilateral radial nerve neuropathy

Prior ipsilateral forearm surgery affecting nerve anatomy

Active donor-site infection

Trial design

Design model

Parallel

Treatments tested in this trial

  • Standard Closure (Control)

    Procedure/Surgery

    * Standard RFFF harvest * Split-thickness skin graft (STSG) donor-site closure

  • Avive+ Intervention

    Procedure/Surgery

    * Standard RFFF harvest * Placement of Avive+ Soft Tissue Matrix over the superficial radial nerve * STSG donor-site closure

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Standard Closure (Control)Active comparator 1 intervention
Group B: Avive+ InterventionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Clinically Significant Neuropathic Pain at 6 Months - DN4 score

A DN4 questionnaire score of 4 or higher out of 10 indicates a high probability of neuropathic pain. This validated tool, which can be viewed in this DN4 Questionnaire consists of seven patient-interview questions and three clinician-examination items, with a total score distinguishing neuropathic from non-neuropathic pain. A score greater than or equal to 4 is considered positive for neuropathic pain

Time frame
6 months
2

Clinically Significant Neuropathic Pain at 6 Months - Numeric Rating Scale

Numeric Rating Scale (NRS) is used to measure pain, where 0 is "no pain" and 10 is "worst pain imaginable"

Time frame
6 months

Secondary outcomes

1

Average Pain Severity

Numeric Rating Scale (NRS): Commonly used in healthcare to measure pain, where 0 is "no pain" and 10 is "worst pain imaginable"

Time frame
1, 3, 6, and 12 months
2

Average Sensory Function with Semmes-Weinstein monofilament testing

The Semmes-Weinstein monofilament test is a quick, non-invasive, and objective clinical exam used to evaluate nerve function by measuring skin sensitivity to light touch and pressure.

Time frame
1, 3, 6, and 12 months
3

Average Sensory Function with Static 2-point discrimination

Static 2-point discrimination (2PD) is a clinical test measuring the minimum distance at which a patient can perceive two simultaneous touch stimuli as distinct, rather than one, using a device like an aesthesiometer or disk-criminator.

Time frame
1, 3, 6, and 12 months
4

Percentage of Skin Graft Loss

Measured by percentage of 0-100% total graft loss.

Time frame
up to 3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: